Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Absolute Bioavailability of [14C]AZD9977 in Healthy Men
NCT04686591Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of balcinrenone in heart failure (HF) and chronic kidney disease (CKD), sponsored by AstraZeneca. Primary endpoints: Absolute bioavailability of AZD9977 at 72 hours, Cumulative amount of AZD9977 excreted at 168 hours and 2 more. Started Dec 2020; status: completed.
02
Drugs
balcinrenone
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04686591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04686591.